Objective. Abatacept (ABA) has recently been proposed as second-line treatment in patients
with juvenile idiopathic arthritis (JIA)–associated uveitis refractory to anti–tumor necrosis …

Fibrodysplasia ossificans progressive (FOP) is an ultra-rare genetic disorder that is caused
by a mutation in the ACVR1 gene and provokes severe heterotopic ossification. Since flares …

Introduction: Among the wide spectrum of Biologics used in pediatric rheumatology,
abatacept (ABA) has a special place, which differs from other Biologics with direct anti-cytokine …

Objectives Evaluation of 10 years of the experience of Biologics in children, suffering from
juvenile idiopathic arthritis (JIA) in single center focused for reasons of withdrawal. Methods …

Background Fibrodysplasia Ossificans Progressiva (FOP), also known as a “second skeleton
disease” is extremely rare (1: 2000000) and disabling genetic disorder, caused by mutation …

Background The choice of Biologics in patients with juvenile idiopathic arthritis (JIA) who
have overlap syndrome with juvenile onset of systemic lupus erythematosus (JSLE), juvenile …

The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported
outcome measure that enables a thorough assessment of the disease status in …

Objectives To present clinical observation of a family case (mother and daughter) of eoJIA
with uveitis, homogenous clinical picture in the disease beginning and manifestation of …

Abatacept As First Line Biological Treatment for Severe Juvenile Idiopathic Arthritis-Related
Uveitis. A Multicenter Study IRIS SUrplus Home Sfoglia Macrotipologie & tipologie Autore …

Background: Biological agents (BA), especially TNF inhibitors, are high efficacy options for
current therapy for patients (pts) with juvenile idiopathic arthritis (JIA). They are successfully …